Onco-Summaries: Daily Oncology Updates at a Glance

03/11/2025

Iovance's lifileucel TIL therapy elicited an ORR of 25.6% in previously treated non-sq NSCLC (Ref)

Iovance Biotherapeutics reported interim data from its registrational Phase 2 IOV-LUN-202/NCT04614103 trial of lifileucel monotherapy (autologous TIL therapy) in patients with previously treated advanced non-squamous NSCLC without actionable genetic mutations.

• An ORR of 25.6% (CR: 5.1%) was achieved in a pool of 39 patients

  
  

• At a median follow up of 25.4 mos, the mDOR was NR

  
  

• Iovance will present additional data from the trial at an upcoming medical meeting in 2026

  
  

• The trial is expected to progress in 2026 towards a sBLA for lifileucel in non-squamous NSCLC and a potential launch in H2'27